Rigel Pharmaceuticals, Inc. (RIGL)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
47.25 USD
+0.43
(0.918%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 47.25 |
Hot Take ↕ | Oct. 10, 2026, 10:20 a.m. EDT
Rigel presents a classic biotech dilemma: exceptional balance sheet metrics masking a deteriorating operational reality. The company boasts a fortress-like Return on Equity of 127% and a low P/B ratio, yet it is bleeding cash with negative free flow and shrinking revenues. This disconnect explains the market's hesitation; the stock is trading at a discount because the growth engine is sputtering, despite the management team's ability to generate returns on existing capital. The recent price action shows a recovery from multi-year lows, but the lack of consecutive positive annual returns suggests the market views this as a stabilization rather than a turnaround. With no dividend to provide income and a statistical forecast offering no directional clarity, the investment case relies entirely on a specific clinical catalyst to reignite the growth narrative. Until that happens, the risk-reward profile remains neutral, as the stock is simply waiting for the next binary event to determine its fate. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.100609 |
| MSTL | 0.105215 |
| AutoTheta | 0.107555 |
| AutoARIMA | 0.118766 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 4.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.030 |
| Excess Kurtosis | -0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.391 |
| Revenue per Share | 15.124 |
| Market Cap | 874,223,296 |
| Trailing P/E | 2.82 |
| Forward P/E | 9.57 |
| Beta | 1.19 |
| Profit Margins | 116.30% |
| Website | https://www.rigel.com |
As of Oct. 10, 2026, 10:20 a.m. EDT: Speculators are positioning for volatility rather than a clear directional breakout. Call volume is skewed toward out-of-the-money strikes (55 and 65/70) suggesting a hope for a catalyst-driven rally, while put volume is heavily concentrated deep in-the-money (15, 25, 29 strikes) indicating a hedge against a significant drop to lower valuations. The implied volatility is elevated on these deep puts, reflecting fear of downside risk, while the call side shows 'new flow' at higher strikes, creating a tension between a potential upside pop and a defensive floor.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.66559947 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 900 |
| All Time High | 1,147.5 |
| All Time Low | 6.4 |
| Ask | 53.95 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 220,030 |
| Average Daily Volume3 Month | 278,845 |
| Average Volume | 278,845 |
| Average Volume10Days | 220,030 |
| Beta | 1.187 |
| Bid | 41.28 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 22.806 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 47.25 |
| Current Ratio | 1.941 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 48.515 |
| Day Low | 47.01 |
| Debt To Equity | 9.391 |
| Display Name | Rigel Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Growth | -0.732 |
| Earnings Quarterly Growth | -0.71 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | 89,699,000 |
| Ebitda Margins | 0.32407 |
| Enterprise To Ebitda | 9.222 |
| Enterprise To Revenue | 2.989 |
| Enterprise Value | 827,244,544 |
| Eps Current Year | 3.54272 |
| Eps Forward | 4.93916 |
| Eps Trailing Twelve Months | 16.74 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 624 1101 |
| Fifty Day Average | 46.0758 |
| Fifty Day Average Change | 1.1741982 |
| Fifty Day Average Change Percent | 0.025484052 |
| Fifty Two Week Change Percent | 66.559944 |
| Fifty Two Week High | 52.24 |
| Fifty Two Week High Change | -4.9900017 |
| Fifty Two Week High Change Percent | -0.095520705 |
| Fifty Two Week Low | 24.95 |
| Fifty Two Week Low Change | 22.3 |
| Fifty Two Week Low Change Percent | 0.8937875 |
| Fifty Two Week Range | 24.95 - 52.24 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 975,508,200,000 |
| Float Shares | 14,839,844 |
| Forward Eps | 4.93916 |
| Forward P E | 9.566404 |
| Free Cashflow | -31,758,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 172 |
| Fullday Change | 0.4300003 |
| Fullday Change Percent | 0.9184116 |
| Fullday Price | 47.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.75608003 |
| Gross Profits | 209,271,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03352 |
| Held Percent Institutions | 0.89331 |
| Implied Shares Outstanding | 18,502,080 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,719,446,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. |
| Long Name | Rigel Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 874,223,296 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_33851 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 321,908,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 911,950,960 |
| Number Of Analyst Opinions | 5 |
| Open | 47.01 |
| Operating Cashflow | 79,389,000 |
| Operating Margins | 0.29954 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 650 624 1100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 47.25 |
| Post Market Time | 1,792,094,466 |
| Previous Close | 46.82 |
| Price Eps Current Year | 13.33721 |
| Price Hint | 2 |
| Price To Book | 2.0718231 |
| Price To Sales Trailing12 Months | 3.1584923 |
| Profit Margins | 1.16303 |
| Quick Ratio | 1.584 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.4300003 |
| Regular Market Change Percent | 0.91841155 |
| Regular Market Day High | 48.515 |
| Regular Market Day Low | 47.01 |
| Regular Market Day Range | 47.01 - 48.515 |
| Regular Market Open | 47.01 |
| Regular Market Previous Close | 46.82 |
| Regular Market Price | 47.25 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 167,847 |
| Return On Assets | 0.14951 |
| Return On Equity | 1.26897 |
| Revenue Growth | -0.226 |
| Revenue Per Share | 15.124 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 18,502,080 |
| Shares Percent Shares Out | 0.1529 |
| Shares Short | 2,855,433 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,182,110 |
| Short Name | Rigel Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.15689999 |
| Short Ratio | 12.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | RIGL |
| Target High Price | 85.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 63.0 |
| Target Median Price | 55.0 |
| Total Cash | 95,329,000 |
| Total Cash Per Share | 5.103 |
| Total Debt | 39,950,000 |
| Total Revenue | 276,784,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 16.74 |
| Trailing P E | 2.8225806 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.7294 |
| Two Hundred Day Average Change | 10.520599 |
| Two Hundred Day Average Change Percent | 0.28643537 |
| Type Disp | Equity |
| Volume | 167,847 |
| Website | https://www.rigel.com |
| Zip | 94,080 |